Gene-activating nanomedicine for the tumor-oriented infiltration of T cells to enhance immunotherapy against solid tumors

[1]  Shuang Wang,et al.  Non-invasive activation of intratumoural gene editing for improved adoptive T-cell therapy in solid tumours , 2023, Nature Nanotechnology.

[2]  Leshuai W. Zhang,et al.  Therapeutic dendritic cell vaccines engineered with antigen‐biomineralized Bi2S3 nanoparticles for personalized tumor radioimmunotherapy , 2022 .

[3]  M. Maitland,et al.  CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. , 2021, The New England journal of medicine.

[4]  C. Marr,et al.  Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors , 2021, Science Advances.

[5]  Rosalie M Sterner,et al.  CAR-T cell therapy: current limitations and potential strategies , 2021, Blood Cancer Journal.

[6]  T. Mak,et al.  Beyond immune checkpoint blockade: emerging immunological strategies , 2021, Nature Reviews Drug Discovery.

[7]  J. Hecht,et al.  The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer , 2021, Science Translational Medicine.

[8]  Jiang Ren,et al.  Targeting TGFβ signal transduction for cancer therapy , 2021, Signal Transduction and Targeted Therapy.

[9]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[10]  M. Ibáñez-Hernández,et al.  Strategies for Targeting Gene Therapy in Cancer Cells With Tumor-Specific Promoters , 2020, Frontiers in Oncology.

[11]  Nicholas A. Peppas,et al.  Engineering precision nanoparticles for drug delivery , 2020, Nature reviews. Drug discovery.

[12]  C. Wahl-Schott,et al.  A gene therapy for inherited blindness using dCas9-VPR–mediated transcriptional activation , 2020, Science Advances.

[13]  C. Robert.  A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[14]  Brian Craft,et al.  Visualizing and interpreting cancer genomics data via the Xena platform , 2020, Nature Biotechnology.

[15]  M. Lenardo,et al.  A guide to cancer immunotherapy: from T cell basic science to clinical practice , 2020, Nature Reviews Immunology.

[16]  P. Hegde,et al.  Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.

[17]  R. Brentjens,et al.  Engineering strategies to overcome the current roadblocks in CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[18]  S. Loi,et al.  Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade , 2019, Clinical Cancer Research.

[19]  J. Spicer,et al.  Cytotoxic Chemotherapy as an Immune Stimulus: A Molecular Perspective on Turning Up the Immunological Heat on Cancer , 2019, Front. Immunol..

[20]  Robin L. Jones,et al.  Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial , 2019, Cancer Immunology Research.

[21]  Dennie T. Frederick,et al.  Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.

[22]  Michael Pineda,et al.  Safe CRISPR: Challenges and Possible Solutions. , 2019, Trends in biotechnology.

[23]  You Lu,et al.  Advancements and Obstacles of CRISPR-Cas9 Technology in Translational Research , 2019, Molecular therapy. Methods & clinical development.

[24]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[25]  C. Caux,et al.  Cold Tumors: A Therapeutic Challenge for Immunotherapy , 2019, Front. Immunol..

[26]  Navneet Matharu,et al.  CRISPR-mediated activation of a promoter or enhancer rescues obesity caused by haploinsufficiency , 2019, Science.

[27]  Yang Liu,et al.  Targeting of NLRP3 inflammasome with gene editing for the amelioration of inflammatory diseases , 2018, Nature Communications.

[28]  Jennifer A. Doudna,et al.  CRISPR-Cas guides the future of genetic engineering , 2018, Science.

[29]  M. Sweetser,et al.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis , 2018, The New England journal of medicine.

[30]  J. Wolchok,et al.  Cancer immunotherapy using checkpoint blockade , 2018, Science.

[31]  C. R. Esteban,et al.  In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation , 2017, Cell.

[32]  G. Coukos,et al.  Mechanisms regulating T-cell infiltration and activity in solid tumors. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[34]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[35]  Suzanne F. Jones,et al.  Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma , 2016, Nature Communications.

[36]  Lei S. Qi,et al.  CRISPR/Cas9 in Genome Editing and Beyond. , 2016, Annual review of biochemistry.

[37]  Xiaoxiao Wang,et al.  Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. , 2016, Cancer cell.

[38]  Frederic Bartumeus,et al.  T cell migration, search strategies and mechanisms , 2016, Nature Reviews Immunology.

[39]  Z. Guo,et al.  CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy , 2015, Oncoimmunology.

[40]  E. Puré,et al.  Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells. , 2015, Cancer research.

[41]  K. Odunsi,et al.  Non-redundant Requirement for CXCR3 Signaling during Tumoricidal T Cell Trafficking across Tumor Vascular Checkpoints , 2015, Nature Communications.

[42]  J. Yewdell,et al.  CXCR3 chemokine receptor enables local CD8(+) T cell migration for the destruction of virus-infected cells. , 2015, Immunity.

[43]  Luke A. Gilbert,et al.  Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds , 2015, Cell.

[44]  Alexandro E. Trevino,et al.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.

[45]  J. Doudna,et al.  The new frontier of genome engineering with CRISPR-Cas9 , 2014, Science.

[46]  R. Simon,et al.  CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 , 2013, British Journal of Cancer.

[47]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[48]  Xiao-ling Lu,et al.  A novel recombinant protein of IP10-EGFRvIIIscFv and CD8+ cytotoxic T lymphocytes synergistically inhibits the growth of implanted glioma in mice , 2013, Cancer Immunology, Immunotherapy.

[49]  Chengyu Liu,et al.  Strategies for Designing Transgenic DNA Constructs , 2013, Methods in molecular biology.

[50]  G. Pinkus,et al.  Interferon-γ–Dependent Infiltration of Human T Cells into Neuroblastoma Tumors In vivo , 2009, Clinical Cancer Research.

[51]  Richard P. Harvey,et al.  Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7 , 2007, Proceedings of the National Academy of Sciences.

[52]  L. Tian,et al.  Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma , 2006, Gene Therapy.

[53]  L. Álvarez-Vallina,et al.  Chronic gene delivery of interferon-inducible protein 10 through replication-competent retrovirus vectors suppresses tumor growth , 2005, Cancer Gene Therapy.

[54]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[55]  T. Manabe,et al.  Pivotal Role of CXCR3 in Melanoma Cell Metastasis to Lymph Nodes , 2004, Cancer Research.

[56]  A. Feldman,et al.  Retroviral gene transfer of interferon‐inducible protein 10 inhibits growth of human melanoma xenografts , 2002, International journal of cancer.

[57]  M. Murphy,et al.  Activation of cancer-specific gene expression by the survivin promoter. , 2002, Journal of the National Cancer Institute.

[58]  M. Klüppel,et al.  The mouse tyrosinase promoter is sufficient for expression in melanocytes and in the pigmented epithelium of the retina. , 1991, Proceedings of the National Academy of Sciences of the United States of America.